GeoVax Labs, Inc. New
$0.41
-$0.01 (-3.18%)
$0.40Day Range$0.42
Key Statistics
Market Cap
$3.68M
Shares Outstanding
9.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 1, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$0.41
Day High
$0.42
Day Low
$0.40
Volume
206.9K
VWAP
$0.41
Prev Close
$0.42
Transactions
--
Acc. Volume
--
About GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
PHARMACEUTICAL PREPARATIONSSIC 283419 employees1955 LAKE PARK DRIVE, SMYRNA, GA678-384-7220IPO Feb 1, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000832489
- Composite FIGI
- BBG000BGGJD8
- Share Class FIGI
- BBG001S6ZC26
- Ticker Root
- GOVX
- SIC Code
- 2834
About GeoVax Labs, Inc. New (GOVX) Stock
GeoVax Labs, Inc. New (GOVX) closed the 2026-09-16 session at $0.41, down 3.18% versus the previous close (-0.01). The stock opened at $0.41 and traded between $0.40 and $0.42 during that session. Session trading volume was 207K shares. The volume-weighted average price (VWAP) is $0.41.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
GeoVax Labs, Inc. New has a market capitalization of $3.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. GOVX is listed on the XNAS exchange. The company employs approximately 19 people. GeoVax Labs, Inc. New is headquartered in SMYRNA, GA. The recorded listing date is 1995-02-01.
On this page you can find market GOVX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.